Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itzler

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Pharmacoeconomics|September 18, 2009
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plansRonald R White, Greg Lenhart, Puneet K Singhal, et al.
Vaccine|August 26, 2011
Healthy-days time equivalents for outcomes of acute rotavirus infectionsA Brett Hauber, Robbin Itzler, F Reed Johnson, et al.
The Pediatric Infectious Disease Journal|November 29, 2007
Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infantsMichelle G Goveia, Zoe M Rodriguez, Michael J Dallas, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 11, 2024
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapyRobbin Itzler, Tyler W Buckner, Frank W G Leebeek, et al.
Vaccine|November 3, 2009
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in EuropeTimo Vesikari, Robbin Itzler, Aino Karvonen, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 8, 2008
Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)Timo Vesikari, Robbin Itzler, David O Matson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1Jeroen P Jansen, Rachael Fleurence, Beth Devine, et al.
Journal of Paediatrics and Child Health|April 26, 2012
Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methodsDavid O Matson, Mary Allen Staat, Parvin Azimi, et al.
Human Vaccines|March 29, 2011
Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)Penelope H Dennehy, Timo Vesikari, David O Matson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2David C Hoaglin, Neil Hawkins, Jeroen P Jansen, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Pharmacoeconomics|September 18, 2009
Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plansRonald R White, Greg Lenhart, Puneet K Singhal, et al.
Vaccine|August 26, 2011
Healthy-days time equivalents for outcomes of acute rotavirus infectionsA Brett Hauber, Robbin Itzler, F Reed Johnson, et al.
The Pediatric Infectious Disease Journal|November 29, 2007
Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infantsMichelle G Goveia, Zoe M Rodriguez, Michael J Dallas, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 11, 2024
Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapyRobbin Itzler, Tyler W Buckner, Frank W G Leebeek, et al.
Vaccine|November 3, 2009
RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in EuropeTimo Vesikari, Robbin Itzler, Aino Karvonen, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 8, 2008
Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)Timo Vesikari, Robbin Itzler, David O Matson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1Jeroen P Jansen, Rachael Fleurence, Beth Devine, et al.
Journal of Paediatrics and Child Health|April 26, 2012
Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methodsDavid O Matson, Mary Allen Staat, Parvin Azimi, et al.
Human Vaccines|March 29, 2011
Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)Penelope H Dennehy, Timo Vesikari, David O Matson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2011
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2David C Hoaglin, Neil Hawkins, Jeroen P Jansen, et al.
Pageof 5